Calyxt Inc Stock News

Sumitomo Mitsui Trust Holdings Inc. lowered its stake in Calyxt, Inc. (NASDAQ:CLXT) by 24.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,930,098 shares of the companys stock after selling 609,838 shares during the period. Sumitomo Mitsui Trust Holdings Inc. []

Brokerages predict that Calyxt, Inc. (NASDAQ:CLXT) will report earnings per share of ($0.29) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Calyxt’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.41). Calyxt reported earnings per share of ($0.33) in the same quarter last year, which would suggest […]

Equities research analysts expect Calyxt, Inc. (NASDAQ:CLXT) to post $3.37 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Calyxts earnings. The highest sales estimate is $4.73 million and the lowest is $2.00 million. Calyxt reported sales of $13.93 million during the same quarter last year, which []

Geode Capital Management LLC cut its stake in Calyxt, Inc. (NASDAQ:CLXT) by 35.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 133,458 shares of the companys stock after selling 74,217 shares during the period. Geode Capital Management LLCs holdings in []

ROSEVILLE, Minn., Nov. 23, 2021 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that management will present at the 2021 Canaccord Genui

Calyxt, Inc.'s (CLXT) CEO Michael Carr on Q3 2021 Results - Earnings Call Transcript

Some of the best penny stocks 2021 has offered were some of… The post 5 Penny Stocks To Buy According To Analysts & Price Targets Up To 175% appeared first on Penny Stocks to Buy, Picks, News and In

Calyxt (CLXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ROSEVILLE, Minn., Oct. 5, 2021 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced the launch of a strategic initiative that will focus the

Calyxt Inc (NASDAQ: CLXT) has entered into a research collaboration with a food ingredient manufacturer based in Asia to develop an improved soybean to produce oil as a commercial alternative to pa

ROSEVILLE, Minn., Sept. 28, 2021 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based technology platform company, today announced it entered into a research collaboration with a leading glo

Calyxt, Inc. (CLXT) CEO Michael Carr on Q2 2021 Results - Earnings Call Transcript

Shares of Calyxt (NASDAQ:CLXT) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 36.36% over the past year to ($0.21), which missed the

ROSEVILLE, Minn., Aug. 4, 2021 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based biotechnology platform company, today announced that management will present at the Canaccord Genuity 41st

Calyxt (CLXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.